NCT06861621 STRucturation of Transcript Analysis of Genes Involved in Hereditary Cancers
| NCT ID | NCT06861621 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Rouen |
| Condition | Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2023-09-01 |
| Primary Completion | 2025-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2023-09-01 with a primary completion date of 2025-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Molecular diagnosis using high throughput sequencing has become an essential part of oncogenetic care, making it possible to identify people at risk, to guide surveillance, and to direct preventive surgery and treatment. The quality of this 'precision' care depends on the quality of the interpretation of the genomic variants identified. To be usable in oncogenetics, a genomic variant must be correctly interpreted: pathogenic, benign or of uncertain significance (VSI). The impact of these DNA variants (VSI) on RNA is particularly important for interpretation. Today, due to a lack of resources, joint and systematic DNA/RNA analysis is never carried out. This has inevitably meant that a number of situations of interest have been overlooked. It is now important to go a step further and organise a visible and reliable circuit, allowing routine access to these studies for patients.
Eligibility Criteria
Inclusion Criteria: * Over 18 years of age * Patients seen in oncogenetic consultations and who have given their informed consent for genetic analysis in the context of a major predisposition to breast, ovarian or digestive cancer. * Person who has read and understood the information note and does not object to taking part in the study * Membership of a social security scheme Exclusion Criteria: * Minors * Persons deprived of their liberty or adults under guardianship or incapable of giving their consent * Failure to obtain informed consent
Contact & Investigator
Claude HOUDAYER, Professor
PRINCIPAL INVESTIGATOR
Molecular Genetics Department, UH of Rouen
Frequently Asked Questions
Who can join the NCT06861621 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06861621 currently recruiting?
Yes, NCT06861621 is actively recruiting participants. Contact the research team at Secretariat.DRC@chu-rouen.fr for enrollment information.
Where is the NCT06861621 trial being conducted?
This trial is being conducted at Caen, France, Lille, France.
Who is sponsoring the NCT06861621 clinical trial?
NCT06861621 is sponsored by University Hospital, Rouen. The principal investigator is Claude HOUDAYER, Professor at Molecular Genetics Department, UH of Rouen. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.